Mind Medicine (MNMD) Stock Forecast & Price Target

Compare

1,790 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MNMD Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Mind

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MNMD Stock 12 Month Forecast

Average Price Target

$23.22

▲(268.57%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months. The average price target is $23.22 with a high forecast of $55.00 and a low forecast of $16.00. The average price target represents a 268.57% change from the last price of $6.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","17":"$17","30":"$30","43":"$43","56":"$56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17,30,43,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,11.135384615384616,14.79076923076923,18.446153846153845,22.10153846153846,25.756923076923076,29.41230769230769,33.067692307692305,36.72307692307692,40.378461538461536,44.033846153846156,47.68923076923076,51.34461538461538,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,8.69076923076923,9.901538461538461,11.112307692307692,12.323076923076922,13.533846153846152,14.744615384615384,15.955384615384615,17.166153846153847,18.376923076923077,19.587692307692308,20.798461538461538,22.00923076923077,{"y":23.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,8.135384615384616,8.79076923076923,9.446153846153846,10.101538461538462,10.756923076923076,11.412307692307692,12.067692307692308,12.723076923076924,13.378461538461538,14.033846153846154,14.689230769230768,15.344615384615384,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$23.22

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joel BeattyRobert W. Baird

Robert W. Baird

$27→$16

Buy

153.97%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Marc GoodmanLeerink Partners

Leerink Partners

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Analysts Conflicted on These Healthcare Names: Mind Medicine (NASDAQ: MNMD), RAPT Therapeutics (NASDAQ: RAPT) and LifeMD (NASDAQ: LFMD)

Rudy LiChardan Capital

Chardan Capital

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), IGM Biosciences (NASDAQ: IGMS) and ALX Oncology Holdings (NASDAQ: ALXO)

Francois BriseboisOppenheimer

Oppenheimer

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (NASDAQ: MNMD), SurModics (NASDAQ: SRDX) and Enhabit, Inc (NYSE: EHAB)As MNMD continues to execute across the board, we reiterate our Outperform rating and $20 PT.

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$16

Buy

153.97%

Upside

Reiterated

03/06/25

Buy Recommendation for Mind Medicine: Promising Phase 3 Trials and Undervalued Market Potential

Brian AbrahamsRBC Capital

RBC Capital

$21

Buy

233.33%

Upside

Initiated

03/06/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), Elevation Oncology (NASDAQ: ELEV) and Xeris Pharmaceuticals (NASDAQ: XERS)

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$55

Buy

773.02%

Upside

Reiterated

03/06/25

Mind Medicine's Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial PositionValuation and Risks. We assess MindMed using a discounted cash flow (DCF)-based valuation methodology. We assign a probability of success for in GAD and 55% in MDD. We model annual gross equity raises of $100M-$150M in 2026E and 2027E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $4.3B and a $55 price target.

Michael OkunewitchMaxim Group

Maxim Group

$18

Buy

185.71%

Upside

Reiterated

03/06/25

Mind Medicine's Strategic Initiatives and Financial Health Drive Buy Rating

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$23

Buy

265.08%

Upside

Initiated

01/28/25

Mind Medicine initiated with an Outperform at Evercore ISIMind Medicine initiated with an Outperform at Evercore ISI

Jason WittesRoth MKM

Roth MKM

$36

Buy

471.43%

Upside

Reiterated

07/24/24

Buy Rating on MindMed's MM120: Promising Long-Term Efficacy and Safety in Anxiety Treatment Trials

Elemer PirosLucid Capital

Lucid Capital

$28

Buy

344.44%

Upside

Reiterated

04/04/24

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joel BeattyRobert W. Baird

Robert W. Baird

$27→$16

Buy

153.97%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Marc GoodmanLeerink Partners

Leerink Partners

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Analysts Conflicted on These Healthcare Names: Mind Medicine (NASDAQ: MNMD), RAPT Therapeutics (NASDAQ: RAPT) and LifeMD (NASDAQ: LFMD)

Rudy LiChardan Capital

Chardan Capital

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), IGM Biosciences (NASDAQ: IGMS) and ALX Oncology Holdings (NASDAQ: ALXO)

Francois BriseboisOppenheimer

Oppenheimer

$20

Buy

217.46%

Upside

Reiterated

03/07/25

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$16

Buy

153.97%

Upside

Reiterated

03/06/25

Buy Recommendation for Mind Medicine: Promising Phase 3 Trials and Undervalued Market Potential

Brian AbrahamsRBC Capital

RBC Capital

$21

Buy

233.33%

Upside

Initiated

03/06/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), Elevation Oncology (NASDAQ: ELEV) and Xeris Pharmaceuticals (NASDAQ: XERS)

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$55

Buy

773.02%

Upside

Reiterated

03/06/25

Michael OkunewitchMaxim Group

Maxim Group

$18

Buy

185.71%

Upside

Reiterated

03/06/25

Mind Medicine's Strategic Initiatives and Financial Health Drive Buy Rating

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$23

Buy

265.08%

Upside

Initiated

01/28/25

Mind Medicine initiated with an Outperform at Evercore ISIMind Medicine initiated with an Outperform at Evercore ISI

Jason WittesRoth MKM

Roth MKM

$36

Buy

471.43%

Upside

Reiterated

07/24/24

Buy Rating on MindMed's MM120: Promising Long-Term Efficacy and Safety in Anxiety Treatment Trials

Elemer PirosLucid Capital

Lucid Capital

$28

Buy

344.44%

Upside

Reiterated

04/04/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mind Medicine

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+8.56%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +8.56% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+17.33%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +17.33% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

14/22 ratings generated profit

Average Return

+39.04%

reiterated a buy rating last month

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +39.04% per trade.

2 Years

xxx

Success Rate

15/22 ratings generated profit

Average Return

+41.48%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +41.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNMD Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MNMD has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MNMD average Analyst price target in the past 3 months is 23.22.

Each month's total comprises the sum of three months' worth of ratings.

MNMD Financial Forecast

MNMD Earnings Forecast

Next quarter’s earnings estimate for MNMD is -$0.37 with a range of -$0.40 to -$0.29. The previous quarter’s EPS was -$0.27. MNMD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.10% of the time in the same period. In the last calendar year MNMD has Outperformed its overall industry.

No data currently available

MNMD Sales Forecast

Next quarter’s sales forecast for MNMD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MNMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year MNMD has Preformed in-line its overall industry.

MNMD Stock Forecast FAQ

What is MNMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Mind Medicine’s 12-month average price target is 23.22.

What is MNMD’s upside potential, based on the analysts’ average price target?

Mind Medicine has 268.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MNMD a Buy, Sell or Hold?

Mind Medicine has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mind Medicine’s price target?

The average price target for Mind Medicine is 23.22. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $16.00. The average price target represents 268.57% Increase from the current price of $6.3.

What do analysts say about Mind Medicine?

Mind Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MNMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mind Medicine (MNMD) Stock Forecast & Price Target

MNMD Analyst Ratings

MNMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mind Medicine

MNMD Analyst Recommendation Trends

MNMD Financial Forecast

MNMD Earnings Forecast

MNMD Sales Forecast

MNMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts